Carlsmed, Inc. ( (CARL) ) has released its Q3 earnings. Here is a breakdown of the information Carlsmed, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Carlsmed, Inc., a medical technology company specializing in AI-enabled personalized spine surgery solutions, has reported its financial results for the third quarter of 2025, showcasing significant growth and strategic advancements.
In the third quarter of 2025, Carlsmed achieved a remarkable 98% increase in revenue year-over-year, reaching $13.1 million. The company also raised its full-year revenue guidance to between $49 million and $50 million, reflecting an anticipated growth of 80% to 84% over the previous year.
Key financial highlights include an expansion of gross margins to 76% and a notable increase in surgeon users by over 70% year-over-year. The company also reduced lead times for its aprevo interbody implants to within eight business days. Strategic achievements include securing NTAP reimbursement for cervical procedures and successfully completing over 50 cervical aprevo procedures.
Despite these positive developments, Carlsmed reported a net loss of $8.5 million for the third quarter, slightly higher than the $7.8 million loss in the same period last year. Operating expenses rose to $19.0 million, driven by increased investments in research, sales, and administrative functions.
Looking ahead, Carlsmed is optimistic about its growth trajectory, with plans to launch its cervical spine platform in early 2026. The company remains focused on scaling its transformative digital surgery approach to improve patient outcomes and drive long-term growth.